A clinical trial study to check effectiveness and safety of intrauterine misoprostol during cesarean section to prevent primary Postpartum Hemorrhage

The efficacy and safety of intrauterine Misoprostol during Cesarean section in prevention of Primary Postpartum Hemorrhage-A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/029540

Enrollment

150

Registered

2020-12-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: Misoprostol Drug: Both groups will receive intravenous infusion of 10IU oxytocin diluted to 500ml of normal saline for 30 minutes after delivery of the neonate.Along with that study gro

Eligibility

Inclusion criteria

Inclusion criteria: Gestational age of 37-40 completed weeks Singleton pregnancy Uncomplicated pregnancy No contraindications to prostaglandins No history of coagulopathy Accepting to participate in the study

Exclusion criteria

Exclusion criteria: Women with anemia(haemoglobin Preterm pregnancy Postterm pregnancy Antepartum haemorrhage History of Coagulopathy/preexisting maternal hemorrhagic disease

Design outcomes

Primary

Measure	Time frame
Assessment of amount of intraoperative and postoperative blood loss(within 24hrs of CS) Timepoint: within 24hrs of cesarean section	—

Secondary

Measure	Time frame
Differences between pre and post operative hemoglobin concentration Differences between pre and post operative hematocrits values Need for additional uterotonic drugs Incidence of side effectsTimepoint: within 24 hours of cesarean section	—

Countries

India

Contacts

Public ContactShivangi Tiwari

Jawahar Lal Nehru Medical College And Hospital

shivangi131995@gmail.com8439352615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026